To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Serentis Starts Phase II Clinical Trial in Pruritus of Skin Disease
Read time: Less than a minute
Serentis has announced that it has started a phase II clinical trial in pruritus associated with atopic dermatitis (AD), a type of eczema. Pruritus, more commonly known as itch, is a major symptom of AD. The lack of effective treatments of pruritus has been identified as a major unmet medical need for patients with AD.
The phase II, double blind, vehicle-controlled cross-over study is designed to determine the anti-pruritic efficacy, safety and local dermal toleration of SRD174 cream in patients with AD. The study is being conducted in 12 sites in the US.
Tim Sharpington, Serentis’ Chief Executive Officer said, “SRD174 is an innovative product with the potential to address a significant unmet need in the treatment of dermatological conditions. The initiation of this phase II study is an important milestone in the development of our clinical pipeline.”
Results from the trial are expected later in the autumn of 2009.
The phase II, double blind, vehicle-controlled cross-over study is designed to determine the anti-pruritic efficacy, safety and local dermal toleration of SRD174 cream in patients with AD. The study is being conducted in 12 sites in the US.
Tim Sharpington, Serentis’ Chief Executive Officer said, “SRD174 is an innovative product with the potential to address a significant unmet need in the treatment of dermatological conditions. The initiation of this phase II study is an important milestone in the development of our clinical pipeline.”
Results from the trial are expected later in the autumn of 2009.
